Navigation Links
Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences
Date:11/9/2011

e 2 clinical development for the prophylaxis of cytomegalovirus (CMV) and the preemption and treatment of adenovirus infection in hematopoietic cell transplant recipients. Data from an ongoing, placebo-controlled Phase 2 CMV prophylaxis trial is expected during the first quarter of 2012.  In an emergency IND cohort of adenovirus-infected transplant recipients, CMX001 has demonstrated its ability to reduce viremia and improve survival.  To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.  

Chimerix's second clinical-stage antiviral compound, CMX157, is a lipid-antiviral-conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate.  CMX157 is in development as a potent nucleoside analogue against HIV and HBV infections, and has the potential to directly address several limitations of current therapies.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, providing pharmacokinetic data which support the compound's enhanced characteristics.  

Led by an experienced antiviral drug development team, Chimerix is also leveraging its lipid conjugate t
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
2. Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
3. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
4. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
5. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
6. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
7. Chimerix to Present at the Citi 2011 Global Health Care Conference
8. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
9. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
10. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
11. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 21, 2015 Research and Markets ( ... "Pharmaceutical Industry in China to 2020: An ... Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, ... This report tackles not only ... but also home grown companies and ...
(Date:7/28/2015)... 28, 2015  Alere Inc. (NYSE: ALR ), ... it will release its financial results for the second ... a conference call beginning at 8:30 a.m. ET on ... provide business updates. The conference call ... of Alere,s website, or accessed directly through the following ...
(Date:7/28/2015)... VANCOUVER and HOUSTON, TX , ... "Company") (NASDAQ: EPIX ) is pleased to announce that ... be listed and commence trading on the Toronto Stock Exchange ... the opening of trading on Tuesday, July 28, 2015 under ... delisted from the TSX Venture Exchange. About ...
Breaking Medicine Technology:Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2Alere to Report Second Quarter 2015 Financial Results on August 4, 2015 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
(Date:7/28/2015)... ... 28, 2015 , ... Today, enterprise request management (ERM) and ... upgrade and expansion of its ERM system using Kinetic Data software. ... 134 countries supplying a wide range of business and residential energy products and ...
(Date:7/28/2015)... ... July 28, 2015 , ... BiologicsMD, ... combination products for the treatment of bone disorders and conditions of hair loss, ... entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". The issued patent claims ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new ... workers than they are in the general population. Surviving Mesothelioma has just posted ... , Researchers at Taiwan’s National Health Research Institutes and three Taiwanese universities ...
(Date:7/28/2015)... ... ... Women fear developing Alzheimer's disease more than having a heart attack or stroke ... but there is little an individual can do to arrest the progress of Alzheimer's ... reports the July 2015 Harvard Women's Health Watch . , "There are now ...
(Date:7/28/2015)... ... ... Every summer, the public is reminded to leave the Fourth of July ... own neighborhoods. Unfortunately, according to a recent report issued by the U.S. Consumer Product ... Eye Injuries Caused by Fireworks Doubled in Last 3 Years ," the number of ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:New Findings Suggest Mesothelioma is Not the Only Cancer Threat for Shipbreakers, According to Surviving Mesothelioma 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3
... in Boston suggests that daily use of inhaled steroids may ... ,Dr. Gregory Sawicki insists that a study ... that over a period of one-year, children who used inhaled ... having well-controlled asthma in comparison to non-users of steroids. ...
... Nottingham experts have joined forces with Canadian biotech company ... the fight against food poisoning . ,They ... methods for the control of Campylobacter the commonest ... Wales, according to the Health Protection Agency. Campylobacters are ...
... University of Warwick have found that sexual orientation has a ... navigating with a map in a car but that ... and withers all mens minds alike just ahead of womens. ... BBC to collect data from over 198,000 people aged 2065 ...
... that women who regularly enjoy an alcoholic drink or two ... heart attack than women who are life-time abstainers. ,Women ... a month were nearly three times more likely to suffer ... ,One difference in the protective pattern among drinkers involved those ...
... science could employ aspirin and new aspirin-like drugs for ... ,The study was conducted by a ... Ireland Cancer Center. ,As part of the ... use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), also ...
... improvements in the ability to diagnose malaria, these ... patients with negative test results are often prescribed ... ,The recent introduction of the effective but ... for malaria throughout Africa has led to renewed ...
Cached Medicine News:Health News:Use of Inhaled Steroids on Daily Basis may Not Control Childhood Asthma 2Health News:Experts to Develop New Weapons Against Food Poisoning 2Health News:Experts to Develop New Weapons Against Food Poisoning 3Health News:A Tipple a Day may Be heart Friendly for Women 2Health News:Aspirin may Help to Prevent Colon Cancer in High-risk Individuals 2Health News:Diagnostic Tests for Malaria Underused in Zambia 2
... assays are designed for ... 2000, a high-throughput, continuous ... IMMULITE 2000 offers testing ... a rapidly expanding menu ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 100 mm x 100 ...
... specimen radiography. The XPERT represents a research tool ... gray in every digital x-ray image, thus being ... that heretofore were lost to the human eye. ... 2 to 8 x 8 in size, multi-color ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
Medicine Products: